Cri-report -Research Report on China's Diabetes Drug Market, 2013-2017


The market size of China's diabetes drugs rises year by year, which always presents a rapidly growing trend in recent years, reaching CNY 15.86 billion in 2011, with an increase of 18.2% YOY.

Shanghai (I-Newswire) January 21, 2013 - (CRI-report) -Diabetes refers to a series of metabolic disorder syndrome such as sugars, proteins, fat, water and electrolyte that are triggered by islet dysfunction and insulin resistance, and the latter is caused by the actions of various pathogenic factors such as genetic factors, immune disorders, microbial infections and their toxins, free radical toxins, psychological factors on body. In recent years, with the development of China's economy and improvement in people's living standards, the incidence and morbidity rates of diabetes also present the increasing trend year by year.

In China, with the aggravation of aging degree, improvement in living standards and increase in obese groups caused by unhealthy lifestyles, the prevention and treatment of diabetes are increasingly severe. Since China carried out the first survey on diabetes epidemiology in 1980, the morbidity rate of diabetes increases from less than 1% then to about 10% currently. Following tumors and cardiovascular diseases, diabetes becomes the third-largest chronic disease severely threatening people's health. In 1994, diabetics only accounted for 2.5% of the population in China. This figure increased to 5.5% in 2002 and 9.7% in 2008.

In China, the diabetes morbidity rate of people aged above 20 has reached over 9.7%, and the morbidity rate of pre-diabetes (impaired fasting glucose and impaired glucose tolerance) has reached 15.5%. In developed regions of China, diabetics in the rural population are far less than that in the urban population. However, the morbidity rate of pre-diabetes, i.e., impaired glucose regulation, in the rural population is higher than that in the urban population, whether in developed or economically-backward areas. In economically-developed regions, the diabetes morbidity rate of the urban population is 13.6%, and that of the rural population is 16.6%. In medium-developed regions, the diabetes morbidity rate of the urban population is 15.6%, and that of the rural population is 20%. This also shows that, with the development of economy and changes in lifestyles, the rural population are potential groups who are more likely to suffer from diabetes.

Full report: http://www.cri-report.com/drug/9850-research-report-on-china-s-diabetes-drug-market-2013-2017.html

Drug treatment is the focus of the treatment of diabetes. In addition to a small part of patients with type II diabetes which can be controlled through diet therapy and exercise therapy, the rest all need drug treatment. Diabetes drugs include Chinese patent drugs and western drugs, of which the latter is in a dominant position, while the former is in an auxiliary position in the treatment of diabetes.

With the increase in diabetes morbidity rate, residents' income levels and medical levels, the market size of China's diabetes drugs rises year by year, which always presents a rapidly growing trend in recent years, reaching CNY 15.86 billion in 2011, with an increase of 18.2% YOY.

In China, insulin preparations are always leaders in diabetes drug market, and the market share grows year by year recently, reaching 37.75% in 2011, with promising market prospects. Acarbose ranked the second. Before 2010, the share declined year after year, which slightly rebounded in 2011. Market shares of other varieties are all very low, which cannot threaten the market positions of insulin preparations and Acarbose.

The market size of China's diabetes drugs is expected to maintain an annual growth rate of over 18% from 2013 to 2017.

More following information can be acquired through this report:
-Incidence of Diabetes in China
-Market Situation of China's Hospital-use Diabetes Drugs
-Competition in China's Diabetes Drug Market
-Development Trends of Diabetes Treatment Technologies and Market in China

- Following people are recommended to buy this report:
- Diabetes Drug Manufacturers
- Pharmaceutical Trade Enterprises and Hospitals
- Investors/Research Institutions Focusing on Diabetes Drugs

Full report: http://www.cri-report.com/drug/9850-research-report-on-china-s-diabetes-drug-market-2013-2017.html






About China Research and Intellgence

Market research provider in China, conducting feasibility study/survey/interview/fous group/industry   More.. research, aiming to deliver success to you. more information: http://www.cri-report.comLess..

Contact Information

China Research and Intellgence
Angela Zhang
Shanghai, China
02, No.48, Lane 3899, Shangnan Road, Pudong
200124
Phone : 862168521029

Published in:

Business

Published On:

January 21, 2013

Print Release:

Print Release

If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the I-Newswire.com press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.


Related Releases

Vigneshwara Offers Best Return on Your Investment
Vigneshwara group is one of the professionally and reputed realty group and has emerged as a front runners in terms of their innovation and technical skill. Their concepts are reflection of futuristic innovation and truly a pleasure to eyes.

Merits and Demerits of Cranes and Its Components
Cranes are industrial machines that are in the main used for materials movements in construction sites, Production halls, assembly lines, power stations etc. This article contains all about the merits and demerits of single or double girder cranes.

L&T Is Now a Real Estate Developer! L&T Launches New Luxurious Project in Mumbai - by Ray White Gurgaon
L&T Realty Launches CRESCENT BAY in Parel, Mumbai. The wait is over!!!

Now Get A Home Loan In Australia If You Got A Permanent Work Visa
This PR is intended to share an update pertaining to the home loans requirements for all those visa holders, where the visa category allows them to stay and work in Australia on a permanent basis.

EVO Payments International and PAY.ON Partner on Quick Interface for SME Merchants
PAY.ON, the world's leading operator of web-based, omnichannel payment infrastructure systems, and EVO Payments International (EVO), a leading card payment acquirer and payment service provider in the United States